Policy & Regulation
Tevogen Bio submits clinical trials of T Cell IND with FDA to develop treatment for COVID-19
15 October 2020 -

Healthcare company Tevogen Bio revealed on Wednesday that it has filed its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to develop a COVID-19 treatment using proprietary antigen specific T cell technology.

In partnership with Dr Neal Flomenberg, a renowned bone marrow transplant expert and chair of the Department of Medical Oncology at Thomas Jefferson University, the company plans to evaluate T cell technology to treat hospitalized COVID-19 patients.

Utilising Tevogen's proprietary immunotherapy platform and Dr Flomenberg's expertise in research and the transplantation of T cells, the partnership will conduct clinical trials of T cell treatments for COVID-19. The T cells will be generated in the laboratory and administered to the very ill Corona patients. The body generates specific T cells to rid itself of viruses including COVID-19 in normal circumstances.

Additionally, Yale-trained infectious disease epidemiologist Dr Ryan Saadi is leading the company's efforts to develop a COVID-19 curative treatment.



Related Headlines